Regeneron Pharmaceuticals Investor Presentation — November 2018

Document content

NOTE REGARDING FORWARD -LOOKING STATEMENTS AND NON -

GAAP FINANCIAL MEASURES

2This presentation includes forward -looking statements that involve risks and uncertainties relating to future events and the fut ure performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”),

and actual events or results may differ materially from these forward -looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar

expressions are intended to identify such forward -looking statements, although not all forward -looking statements contain these identifying words. These statements concern, and these risks and uncertainties include,

among others, the nature, timing, and possible success and therapeutic applications of Regeneron’s products, product candidat es,and research and clinical programs now underway or planned, including without

limitation EYLEA®(aflibercept) Injection, Dupixent®(dupilumab ) Injection, Praluent®(alirocumab) Injection, Kevzara®(sarilumab ) Injection, Libtayo®(cemiplimab ) Injection, fasinumab ,evinacumab , Regeneron’s earlier -

stage product candidates, and the use of human genetics in Regeneron’s research programs; the extent to which the results fro m Regeneron’s research programs or preclinical testing may lead to advancement of

product candidates to clinical trials or therapeutic applications; unforeseen safety issues resulting from the administration ofproducts and product candidates in patients, including serious complications or side effects

in connection with the use of Regeneron’s product candidates in clinical trials; the likelihood and timing of possible regula tory approval and commercial launch of Regeneron’s late -stage product candidates and new

indications for marketed products, including without limitation EYLEA, Dupixent , Praluent , Kevzara , Libtayo , fasinumab , and evinacumab ; the likelihood and timing of achieving any of the anticipated milestones

described in this presentation; the extent to which the results from the research and development programs conducted by Regen eron or its collaborators may be replicated in other studies and lead to therapeutic

applications; ongoing regulatory obligations and oversight impacting Regeneron’s marketed products (such as EYLEA, Dupixent , Praluent , Kevzara , and Libtayo ), research and clinical programs, and business,

including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which m ay delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s

products and product candidates; competing drugs and product candidates that may be superior to Regeneron’s products and prod uctcandidates; uncertainty of market acceptance and commercial success of